Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Hua Medicine (华领医药) IPO: Little Upside to Fair Value

Hua Medicine (华领医药) IPO: Thoughts on Valuation

Hua Medicine (华领医药) IPO: Reviving Roche's Failed Attempt?

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Hua Medicine Ltd / Equity Capital Markets

<p>Hua Medicine is the third biotech companies to list in Hong Kong without a profit under the amended listing rules. The stock debuted last Friday with a flat return on the first day. In this insight, we will do a review of our call and analyse the stock's performance post listing. We will also discuss the level at which we would be buying.</p>

Hua Medicine is the third biotech companies to list in Hong Kong without a profit under the amended listing rules. The stock debuted last Friday with a flat return on the first day. In this insight, we will do a review of our call and analyse the stock's performance post listing. We will also discuss the level at which we would be buying.

Hua Medicine (华领医药) Post-Listing: Thin Volume and Limited Upside